Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Nivolumab plus chemotherapy versus chemotherapy alone in patients with previously untreated advanced or recurrent gastric/gastroesophageal junction (G/GEJ) cancer: ATTRACTION-4 (ONO-4538-37) study

Date

21 Sep 2020

Session

Presidential Symposium III

Presenters

Narikazu Boku

Citation

Annals of Oncology (2020) 31 (suppl_4): S1142-S1215. 10.1016/annonc/annonc325

Authors

N. Boku1, M.H. Ryu2, D. Oh3, S.C. Oh4, H.C. Chung5, K. Lee6, T. Omori7, K. Shitara8, S. Sakuramoto9, I.J. Chung10, K. Yamaguchi11, K. Kato12, S.J. Sym13, S. Kadowaki14, K. Tsuji15, J. Chen16, L. Bai17, L. Chen18, Y. Kang19

Author affiliations

  • 1 Department Of Gastrointestinal Medical Oncology, National Cancer Center Hospital, 1040045 - Tokyo/JP
  • 2 Oncology Dept, Asan Medical Center - University of Ulsan College of Medicine, 138-931 - Seoul/KR
  • 3 Internal Medicine, Seoul National University Hospital, 110-744 - Seoul/KR
  • 4 Dept Of Medical Oncology, Korea University Guro Hospital, Seoul/KR
  • 5 Medical Oncology Dept, Yonsei University, 03722 - Seoul/KR
  • 6 Medical Oncology, Seoul National University Bundang Hospital, Seoul National University College of Medicine, 13620 - Seongnam, Gyeonggi-do/KR
  • 7 Gastroenterological Surgery, Osaka International Cancer Institute, Osaka/JP
  • 8 Department Of Gastrointestinal Oncology, National Cancer Center Hospital East, 277-8577 - Kashiwa/JP
  • 9 Department Of Gastroenterology, Saitama Medical University, International Cancer Center, Saitama/JP
  • 10 Internal Medicine/hemato-oncology, Chonnam National University Hwasun Hospital, 58128 - Hwasun/KR
  • 11 Department Of Gastroenterological Chemotherapy, Cancer Institute Hospital of JFCR, 135-8550 - Tokyo/JP
  • 12 Department Of Gastrointestinal Medical Oncology, National Cancer Center Research Institute - Tsukiji Campus, 104-0045 - Chuo-ku/JP
  • 13 Internal Medicine, Division Of Medical Oncology, Gachon University Gil Medical Center, Incheon/KR
  • 14 Department Of Clinical Oncology, Aichi Cancer Center Hospital, 464-8681 - Nagoya/JP
  • 15 Gastroenterology, Ishikawa Prefectural Central Hospital, Ishikawa/JP
  • 16 Division Of Hematology-oncology, Chang Gung Memorial Hospital at Linkou, Taoyuan City/TW
  • 17 Division Of Hematology And Oncology, Department Of Internal Medicine, China Medical University Hospital, 404 - Taichung/TW
  • 18 National Cheng Kung University Hospital, National Institute of Cancer Research, Tainan/TW
  • 19 Department Of Oncology, Asan Medical Center, University of Ulsan College of Medicine, 138-931 - Seoul/KR
More

Resources

Login to access the resources on OncologyPRO.

Abstract LBA7_PR

Background

Nivolumab has a survival benefit for heavily pretreated patients with advanced or recurrent G/GEJ cancer. ATTRACTION-4 is a randomized, multicenter, phase 2/3 study to evaluate the efficacy and safety of nivolumab plus chemotherapy vs. chemotherapy as first-line treatment in patients with HER2-negative, advanced or recurrent G/GEJ cancer. Here we report the results of the double-blind phase III part.

Methods

Patients were randomized 1:1 to receive nivolumab plus chemotherapy (N+C, S-1 plus oxaliplatin or capecitabine plus oxaliplatin) or placebo plus chemotherapy (C). Nivolumab or placebo was intravenously administered every 3 weeks until disease progression or unacceptable toxicity. Tumor assessment was performed every 6 weeks through week 54, then repeated every 12 weeks. The co-primary endpoints were centrally-assessed PFS and OS, and it was prespecified that the primary objective is deemed to be achieved if at least one of the null hypotheses of the primary endpoints is rejected.

Results

A total of 724 Asian patients were randomized to N+C (n=362) or C (n=362) between Mar 7, 2017, and May 10, 2018. At the interim analysis primary for PFS with the median follow-up period of 11.6 mo, PFS was significantly improved in N+C vs. C (HR 0.68; 98.51% CI 0.51-0.90; p=0.0007; median PFS, 10.5 vs. 8.3 mo), meeting the primary endpoint. At the final analysis primary for OS with the median follow-up period of 26.6 mo, there was no statistically significant difference (HR 0.90; 95% CI 0.75-1.08; p=0.257; median OS, 17.5 vs. 17.2 mo), while PFS was continuously longer in N+C than in C. ORR was higher in N+C than in C (57.5 vs. 47.8%; p=0.0088). The incidences of grade 3 to 5 treatment-related adverse events were 57.9% in N+C and 49.2% in C.

Conclusions

PFS was significantly improved in N+C vs. C, achieving the primary objective. The combination of nivolumab and chemotherapy, which demonstrated clinically meaningful efficacy in PFS and ORR with a manageable safety profile but not statistically significant improvement in OS, can be considered a new first-line treatment option in advanced or recurrent G/GEJ cancer.

Clinical trial identification

NCT02746796; Study start date: March 2016.

Editorial acknowledgement

Legal entity responsible for the study

Ono Pharmaceutical Co., Ltd.

Funding

Ono Pharmaceutical Co., Ltd. Bristol-Myers Squibb.

Disclosure

N. Boku: Honoraria (self): Ono; Honoraria (self), Research grant/Funding (institution): BMS; Honoraria (self), Research grant/Funding (institution): Taiho. M.H. Ryu: Honoraria (self), Advisory/Consultancy: Ono; Honoraria (self), Advisory/Consultancy: BMS; Honoraria (self), Advisory/Consultancy: MSD; Honoraria (self), Advisory/Consultancy: Eli Lilly; Honoraria (self), Advisory/Consultancy: Taiho; Honoraria (self), Advisory/Consultancy: Novartis; Honoraria (self), Advisory/Consultancy: Daehwa. D-Y. Oh: Advisory/Consultancy, Research grant/Funding (self): AstraZeneca; Advisory/Consultancy, Research grant/Funding (self): Novartis; Advisory/Consultancy: Genentech; Advisory/Consultancy: Merck Serono; Advisory/Consultancy: Bayer; Advisory/Consultancy: Taiho; Advisory/Consultancy: Aslan; Advisory/Consultancy: Halozyme; Advisory/Consultancy: Zymeworks; Advisory/Consultancy: Celgene; Research grant/Funding (self): Array; Research grant/Funding (self): Eli Lilly; Advisory/Consultancy: Roche. H.C. Chung: Honoraria (self), Advisory/Consultancy, Research grant/Funding (institution): Merck-Serono; Honoraria (self), Advisory/Consultancy, Research grant/Funding (institution): Eli Lilly; Honoraria (self): Foundation Medicine; Advisory/Consultancy, Research grant/Funding (institution): Taiho; Advisory/Consultancy: Celltrion; Advisory/Consultancy, Research grant/Funding (institution): MSD; Advisory/Consultancy, Research grant/Funding (institution): BMS; Advisory/Consultancy: Gloria; Advisory/Consultancy, Research grant/Funding (institution): Beigene; Advisory/Consultancy, Research grant/Funding (institution): Amgen; Advisory/Consultancy: Zymework; Research grant/Funding (institution): GSK; Research grant/Funding (institution): Ono pharmaceutical. K-W. Lee: Honoraria (self): BMS; Honoraria (self): Eli Lilly; Honoraria (self): Genexine; Research grant/Funding (institution): Macrogenics; Research grant/Funding (institution): MSD; Research grant/Funding (institution): Ono pharmaceutical; Research grant/Funding (institution): Green Cross Corp.; Research grant/Funding (institution): Aslan Pharmaceuticals; Research grant/Funding (institution): AstraZeneca/MedImmune; Research grant/Funding (institution): Five Prime Therapeutics; Research grant/Funding (institution): LSK BioPharma; Research grant/Funding (institution): Merck KGaA; Research grant/Funding (institution): Array BioPharma; Research grant/Funding (institution): Pharmacyclics; Research grant/Funding (institution): Pfizer; Research grant/Funding (institution): ALX Oncology; Research grant/Funding (institution): Zymeworks; Research grant/Funding (institution): BeiGene; Research grant/Funding (institution): Daiichi Sankyo; Research grant/Funding (institution): Taiho Pharmaceutical. K. Shitara: Honoraria (self), Advisory/Consultancy: Novartis; Honoraria (self), Advisory/Consultancy: AbbVie; Honoraria (self): Yakult; Advisory/Consultancy, Research grant/Funding (institution): Astellas; Advisory/Consultancy, Research grant/Funding (institution): Eli Lilly; Advisory/Consultancy: BMS; Advisory/Consultancy: Takeda; Advisory/Consultancy: Pfizer; Advisory/Consultancy, Research grant/Funding (institution): Ono Pharmaceutical; Advisory/Consultancy, Research grant/Funding (institution): MSD; Advisory/Consultancy, Research grant/Funding (institution): Taiho; Advisory/Consultancy: GSK; Research grant/Funding (institution): Sumitomo Dainippon Pharma; Research grant/Funding (institution): Daiichi Sankyo; Research grant/Funding (institution): Chugai; Research grant/Funding (institution): Medi Science. S. Sakuramoto: Research grant/Funding (institution): Ono pharmaceutical; Research grant/Funding (institution): Taiho; Research grant/Funding (institution): Kaken pharmaceutical; Research grant/Funding (institution): Chugai. K. Yamaguchi: Honoraria (institution), Speaker Bureau/Expert testimony: Daiichi Sankyo; Honoraria (institution), Speaker Bureau/Expert testimony: Taiho; Honoraria (institution), Speaker Bureau/Expert testimony: Chugai; Speaker Bureau/Expert testimony: BMS; Honoraria (institution), Speaker Bureau/Expert testimony: Ono Pharmaceutical; Speaker Bureau/Expert testimony: Takeda; Honoraria (institution), Speaker Bureau/Expert testimony: Eli Lilly; Honoraria (institution), Speaker Bureau/Expert testimony: Sanofi; Honoraria (institution): MSD oncology; Honoraria (institution): Sumitomo Dainippon Pharma; Honoraria (institution): Gilead Sciences; Honoraria (institution): Boehringer Ingelheim; Honoraria (institution): Eisai; Honoraria (institution): Yakult Honsya. K. Kato: Advisory/Consultancy, Speaker Bureau/Expert testimony, Research grant/Funding (institution): Ono Pharmaceutical; Advisory/Consultancy, Research grant/Funding (institution): Beigene; Advisory/Consultancy, Research grant/Funding (institution): MSD; Speaker Bureau/Expert testimony: Taiho; Speaker Bureau/Expert testimony: Eli Lilly; Speaker Bureau/Expert testimony, Research grant/Funding (institution): BMS; Research grant/Funding (institution): Shionogi; Research grant/Funding (institution): Merck Bio; Research grant/Funding (institution): Chugai. S. Kadowaki: Honoraria (self), Research grant/Funding (institution): Eli Lilly; Honoraria (self), Research grant/Funding (institution): Taiho; Honoraria (self), Research grant/Funding (institution): Ono Pharmaceutical; Honoraria (self), Research grant/Funding (institution): BMS; Honoraria (self): Yakult Honsya; Honoraria (self): Chugai; Honoraria (self): Bayer; Honoraria (self): Merck; Research grant/Funding (institution): MSD. J-S. Chen: Honoraria (self), Advisory/Consultancy: Ono Pharmaceutical; Honoraria (self): TTY Biopharma; Honoraria (self): MSD oncology; Honoraria (self): MedImmune; Honoraria (self): Merck KGaA; Honoraria (self): Roche; Honoraria (self): AstraZeneca. L-Y. Bai: Honoraria (self): AbbVie; Honoraria (self): Bayer; Honoraria (self): BMS; Honoraria (self): Johnson & Johnson; Honoraria (self): GSK; Honoraria (self): Eli Lilly; Honoraria (self): MSD; Honoraria (self): Novartis; Honoraria (self): Ono Pharmaceutical; Honoraria (self): Pfizer; Honoraria (self): PharmaEngine; Honoraria (self): Roche; Honoraria (self): SynCore Biotechnology; Honoraria (self): Takeda; Honoraria (self): TTY Biopharm. L-T. Chen: Honoraria (self): Ono Pharmaceutical; Honoraria (self): Eli Lilly; Honoraria (self): MSD; Honoraria (self), Advisory/Consultancy: PharmaEngine; Honoraria (self), Research grant/Funding (institution): TTY Biopharm; Honoraria (self), Research grant/Funding (institution): SyncorePharm; Honoraria (self), Research grant/Funding (institution): Novartis; Honoraria (self): AstraZeneca; Honoraria (self): Ipsen; Leadership role: National Institute of Cancer Research, Taiwan; Research grant/Funding (institution): Merck Serono; Research grant/Funding (institution): Polaris; Research grant/Funding (institution): Pfizer; Research grant/Funding (institution): BMS; Licensing/Royalties: ENO-1 mAb from HuniLife; Full/Part-time employment: National Health Research Institutes, Taiwan; Officer/Board of Directors: SinoPharm Taiwan, Ltd. Y-K. Kang: Advisory/Consultancy: ALX Oncology; Advisory/Consultancy: BMS; Advisory/Consultancy: Amgen; Advisory/Consultancy: Daehwa; Advisory/Consultancy: Macrogenics; Advisory/Consultancy: Novartis; Advisory/Consultancy: Surface Oncology; Advisory/Consultancy: Zymeworks. All other authors have declared no conflicts of interest.

Resources from the same session

Q&A and live discussion

Presenter: Andres Cervantes

Session: Presidential Symposium III

Resources:

Webcast

Q&A and live discussion

Presenter: Andres Cervantes

Session: Presidential Symposium III

Resources:

Webcast

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings